Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: "Real World" Data From Germany

Krischan Braitsch; Laura K. Schmalbrock; Paul Jung; Irmgard Bumeder; Philipp Kiewe; Judith S. Hecker; Mareike Verbeek; Jörg Westermann; Lars Bullinger; Ulrich Keller; Florian Bassermann; Jan Krönke; Katharina S. Götze; Kathrin Rieger

doi:10.1097/HS9.0000000000000759

Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: "Real World" Data From Germany

Krischan Braitsch, Laura K. Schmalbrock, Paul Jung, Irmgard Bumeder, Philipp Kiewe, Judith S. Hecker, Mareike Verbeek, Jörg Westermann, Lars Bullinger, Ulrich Keller, Florian Bassermann, Jan Krönke, Katharina S. Götze, Kathrin Rieger

Publikation: Beitrag in Fachzeitschrift › Brief › Begutachtung

1 Zitat (Scopus)

Originalsprache	Englisch
Seiten (von - bis)	E759
Fachzeitschrift	HemaSphere
Jahrgang	6
Ausgabenummer	9
DOIs	https://doi.org/10.1097/HS9.0000000000000759
Publikationsstatus	Veröffentlicht - 9 Sept. 2022

Zugriff auf Dokument

10.1097/HS9.0000000000000759

Andere Dateien und Links

Verknüpfung zur Publikation in Scopus

Dieses zitieren

Braitsch, K., Schmalbrock, L. K., Jung, P., Bumeder, I., Kiewe, P., Hecker, J. S., Verbeek, M., Westermann, J., Bullinger, L., Keller, U., Bassermann, F., Krönke, J., Götze, K. S., & Rieger, K. (2022). Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: "Real World" Data From Germany. HemaSphere, 6(9), E759. https://doi.org/10.1097/HS9.0000000000000759

@article{e5f56bd3c3e54a8c9c20b7e195392348,

title = "Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: {"}Real World{"} Data From Germany",

author = "Krischan Braitsch and Schmalbrock, {Laura K.} and Paul Jung and Irmgard Bumeder and Philipp Kiewe and Hecker, {Judith S.} and Mareike Verbeek and J{\"o}rg Westermann and Lars Bullinger and Ulrich Keller and Florian Bassermann and Jan Kr{\"o}nke and G{\"o}tze, {Katharina S.} and Kathrin Rieger",

year = "2022",

month = sep,

day = "9",

doi = "10.1097/HS9.0000000000000759",

language = "English",

volume = "6",

pages = "E759",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "John Wiley and Sons Inc.",

number = "9",

}

Braitsch, K, Schmalbrock, LK, Jung, P, Bumeder, I, Kiewe, P, Hecker, JS, Verbeek, M, Westermann, J, Bullinger, L, Keller, U, Bassermann, F, Krönke, J, Götze, KS & Rieger, K 2022, 'Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: "Real World" Data From Germany', HemaSphere, Jg. 6, Nr. 9, S. E759. https://doi.org/10.1097/HS9.0000000000000759

Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: "Real World" Data From Germany. / Braitsch, Krischan; Schmalbrock, Laura K.; Jung, Paul et al.
in: HemaSphere, Jahrgang 6, Nr. 9, 09.09.2022, S. E759.

Publikation: Beitrag in Fachzeitschrift › Brief › Begutachtung

TY - JOUR

T1 - Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine

T2 - "Real World" Data From Germany

AU - Braitsch, Krischan

AU - Schmalbrock, Laura K.

AU - Jung, Paul

AU - Bumeder, Irmgard

AU - Kiewe, Philipp

AU - Hecker, Judith S.

AU - Verbeek, Mareike

AU - Westermann, Jörg

AU - Bullinger, Lars

AU - Keller, Ulrich

AU - Bassermann, Florian

AU - Krönke, Jan

AU - Götze, Katharina S.

AU - Rieger, Kathrin

PY - 2022/9/9

Y1 - 2022/9/9

UR - http://www.scopus.com/inward/record.url?scp=85179112321&partnerID=8YFLogxK

U2 - 10.1097/HS9.0000000000000759

DO - 10.1097/HS9.0000000000000759

M3 - Letter

AN - SCOPUS:85179112321

SN - 2572-9241

VL - 6

SP - E759

JO - HemaSphere

JF - HemaSphere

IS - 9

ER -